Phase III double-blind trial comparing low-molecular weight heparin (LMWH) [dalteparin sodium] versus placebo in patients with advanced cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer
- Focus Therapeutic Use
- 13 Jul 2016 Biomarkers information updated
- 24 Nov 2007 Status changed from in progress to completed.
- 28 Sep 2005 New trial record.